Once Weekly HIV Pill: A Potential Game Changer. Phase 3…

Once Weekly HIV Pill: A Potential Game Changer. Phase 3 Trial Results Are In. Published: June 9, 2026 | Category: Infectious Disease, HIV, Pharmacology | TALMedora Editorial One of the biggest challenges in HIV management has always been daily pill burden and adherence. A major new development from Gilead Sciences and Merck may be about to change that, permanently. Two Phase 3 trials, ISLEND-1 and ISLEND-2, have met their primary endpoints for a once-weekly single-tablet HIV regimen combining islatravir and lenacapavir (ISL/LEN). This is significant. If approved, this would be the first ever once-weekly oral HIV treatment available to patients. The primary endpoint for both trials was the proportion of participants with HIV-1 RNA levels ≥ 50 copies/mL at Week 48, measured by the FDA snapshot algorithm. ISL/LEN once weekly was statistically non-inferior to BIKTARVY (bictegravir/emtricitabine/tenofovir alafenamide), the current gold standard daily regimen ISL/LEN once weekly was statistically non-inferior to standard of care daily antiretroviral regimens across multiple drug classes including INSTIs, NRTIs, boosted PIs and NNRTIs Safety